A detailed history of Sphera Funds Management Ltd. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Sphera Funds Management Ltd. holds 133,066 shares of VKTX stock, worth $5.23 Million. This represents 1.55% of its overall portfolio holdings.

Number of Shares
133,066
Holding current value
$5.23 Million
% of portfolio
1.55%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $6.63 Million - $9.38 Million
133,066 New
133,066 $8.42 Million
Q3 2020

Nov 12, 2020

SELL
$5.73 - $8.11 $1.17 Million - $1.66 Million
-205,000 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$4.35 - $8.08 $1.67 Million - $3.11 Million
-385,000 Reduced 65.25%
205,000 $1.48 Million
Q4 2019

Feb 13, 2020

BUY
$6.38 - $8.73 $3.76 Million - $5.15 Million
590,000 New
590,000 $4.73 Million
Q1 2019

May 15, 2019

SELL
$7.58 - $9.94 $5.65 Million - $7.41 Million
-745,727 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$7.16 - $16.21 $816,240 - $1.85 Million
-114,000 Reduced 13.26%
745,727 $5.71 Million
Q3 2018

Nov 14, 2018

BUY
$9.7 - $19.65 $749,839 - $1.52 Million
77,303 Added 9.88%
859,727 $15 Million
Q2 2018

Aug 13, 2018

SELL
$3.88 - $12.74 $3.14 Million - $10.3 Million
-809,992 Reduced 50.87%
782,424 $7.43 Million
Q1 2018

May 10, 2018

SELL
$4.11 - $6.93 $2.27 Million - $3.83 Million
-552,884 Reduced 25.77%
1,592,416 $6.96 Million
Q4 2017

Feb 12, 2018

BUY
$1.74 - $4.34 $3.23 Million - $8.05 Million
1,855,300 Added 639.76%
2,145,300 $8.71 Million
Q3 2017

Nov 09, 2017

BUY
$0.94 - $1.91 $272,600 - $553,900
290,000
290,000 $554,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.01B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.